Lakefront Biotherapeutics (LKFT) Total Liabilities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Total Liabilities data on file, last reported at $139.4 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $139.4 million, down 89.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $139.4 million (down 89.6% YoY), and the FY2025 annual result was $198.6 million, down 84.99% from the prior year.
• Total Liabilities fell to $139.4 million in Q1 2026 per LKFT's latest filing, from $198.6 million in the prior quarter.
• Over five years, Total Liabilities peaked at $2.8 billion in Q1 2022 and troughed at $139.4 million in Q1 2026.
• A 5-year average of $1.5 billion and a median of $1.4 billion in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities decreased 13.44% in 2025, then tumbled 89.6% in 2026.
• A 5-year view of Total Liabilities shows it stood at $2.3 billion in 2022, then dropped by 25.41% to $1.7 billion in 2023, then fell by 21.23% to $1.3 billion in 2024, then slumped by 84.99% to $198.6 million in 2025, then dropped by 29.83% to $139.4 million in 2026.
• Business Quant data shows LKFT's Total Liabilities at $139.4 million in Q1 2026, $198.6 million in Q4 2025, and $1.2 billion in Q3 2025.